NEW YORK (AdAge.com) -- TAP Pharmaceutical has narrowed the review for its heartburn drug Prevacid to two agencies, according to people familiar with the matter.
on the account. Prior to Gillespie, the account was at Cordiant Communications Group's Bates USA, New York.
The two finalists are Interpublic Group of Cos.' McCann-Erickson Worldwide, New York, which is pitching with sibling Gillespie Healthcare, Princeton, N.J., and Omnicom Group's Merkley Newman Harty, New York.
Incumbent is Gillespie
Gillespie is the incumbent
|
A spokeswoman for TAP would only say a decision has not been made.
The account generated $37 million in spending in 2001, according to Taylor Nelson Sofres' CMR.
TAP is based in Lake Forest, Ill., and is a joint venture between Abbott Laboratories and Takeda Chemical Industries.
